Nupharm rebrands itself to Neuraxpharm
NuPharm has rebranded to become Neuraxpharm, in an “exciting new chapter” for the company that “positions Neuraxpharm as a single and differentiated central nervous system (CNS) oriented firm within the European pharmaceutical industry”.
You may also be interested in...
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Neuraxpharm has appointed Craig Bowen as general manager of its UK affiliate at the same time as the European central nervous system specialist has launched its first products in the UK market.
Neuraxpharm has kicked off its operations in Poland with the appointment of Wojciech Góra as general manager of its new Neuraxpharm Polska business.